Back to search
FDAFDA · Food and drugs·Recall number D-0460-2022

Sufentanil Citrate Injection, USP 100 mcg/2 mL (50 mcg/mL) for intravenous and epidural use, Rx only, 2 mL Ampule, Warning - May be habit forming, Preservative Free, Manufactured by Akorn, Inc. Lake Forest, IL 60045, NDC 17478-0050-02.

Published January 19, 2022 · Recall initiated: January 5, 2022

Summary

FDA records drug Class II recall D-0460-2022, published January 19, 2022 and initiated January 5, 2022. Recalling firm: Akorn, Inc.; Status: Terminated; Reported quantity: 31,510 ampules; Lot: Lot # 031489A, Expiration 03/31/2022. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Subpotent Drug: Out of specification for assay at the 30-month stability timepoint.

What to do

Voluntary: Firm initiated · E-Mail

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Akorn, Inc.
Distributor
Nationwide in the USA
Lot
Lot # 031489A, Expiration 03/31/2022
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Sufentanil Citrate Injection, USP 100 mcg/2 mL (50 mcg/mL) for intravenous and epidural use, Rx only, 2 mL Ampule, Warning - May be habit forming, Preservative Free, Manufactured by Akorn, Inc. Lake Forest, IL 60045, NDC 17478-0050-02. recalled?

Yes. FDA published recall D-0460-2022 on January 19, 2022. Reported hazard: Subpotent Drug: Out of specification for assay at the 30-month stability timepoint.

What should I do if I have this product?

Voluntary: Firm initiated · E-Mail